Impact Factor 3.845 | CiteScore 3.92
More on impact ›
The section represents a forum for the publication of cutting edge studies in which drugs, chemicals, endogenous substances, and natural products are studied in complex cellular systems, organ systems, whole animals, or humans. Its purpose is to emphasize the importance of complex systems and whole animal research to the discovery of novel mechanisms of action and novel therapeutic entities. The ultimate goal of pharmacology is the discovery and development of new treatments for human disease. As such, particular emphasis will be placed on studies of phenotypic compound screening in complex in vitro and ex vivo systems, rodent models of disease, large animal models of disease including non-human primates, and early phase clinical drug studies. Emphasis will also be placed on the development of new animal models for human disease, development of new disease biomarkers, and the discovery of new molecular probes for drug discovery. Though drug discovery and development has largely been the province of the pharmaceutical industry, there is a growing component of the science in academic and private settings, and it is expected that contributions will derive from all sectors.
This section will extend beyond the traditional boundaries of pharmacological R&D, which have focused on symptomatic treatment of disease, to include regenerative pharmacology. A working definition of regenerative pharmacology is: “the application of pharmacological sciences to accelerate, optimize, and characterize (either in vitro or in vivo) the development, maturation, and function of bioengineered and regenerating tissues.” This groundbreaking approach has the potential for the curative treatment of human diseases and disorders through modulation of regeneration, repair, and replacement of lost or damaged cells, organs, and tissues. This represents a new frontier for pharmacologists. In addition, it will include consideration of modern drug delivery systems, that is, the diverse set of interdisciplinary technologies currently being developed to overcome barriers that limit the effectiveness of traditional pharmacotherapy. Taken together these technologies extend the realm of deliverable therapeutic agents to a wider array of compounds, including gene therapies, and have obvious implications to the success of Integrative and Regenerative Pharmacology. As such, this section will provide a unique setting for the synthesis and integration of ideas and findings leading to new clinical entities having a variety of disease applications.
Areas covered: - Behavioral pharmacology - Cardiovascular pharmacology - Chemotherapy and neoplastic pharmacology - Cognitive pharmacology - Drug delivery systems - GI and smooth muscle pharmacology - Immunopharmacology - Neuropharmacology - Pulmonary pharmacology - Regenerative pharmacology - Reproductive pharmacology
Indexed in: PubMed, PubMed Central, Scopus, Web of Science, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS)
PMCID: all published articles receive a PMCID
Integrative and Regenerative Pharmacology welcomes submissions of the following article types: Correction, Data Report, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge and Technology and Code.
All manuscripts must be submitted directly to the section Integrative and Regenerative Pharmacology, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Integrative and Regenerative Pharmacology will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Pharmacology.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact email@example.com
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact firstname.lastname@example.org